An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Clinical trial NCT01592370 · COMPLETED
Trial details
- NCT number
- NCT01592370
- Sponsor
- Bristol-Myers Squibb
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-08-02
- Primary completion
- 2020-09-25
- Enrollment
- 320
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.